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PKAcAMP and mTOR signalling pathways control a number of critical cellular processes including metabolism,
protein synthesis, proliferation and cell survival and therefore understanding the signalling events which
integrate these two signalling pathways is of particular interest. In this study, we show that the phar-
macological elevation of [cAMP]i in mouse embryonic ﬁbroblasts (MEFs) and human embryonic kidney 293
(HEK293) cells inhibits mTORC1 activation via a PKA-dependent mechanism. Although the inhibitory effect of
cAMP on mTOR could be mediated by impinging on signalling cascades (i.e. PKB, MAPK and AMPK) that
inhibit TSC1/2, an upstream negative regulator of mTORC1, we show that cAMP inhibits mTORC1 in TSC2
knockout (TSC2−/−) MEFs. We also show that cAMP inhibits insulin and amino acid-stimulated mTORC1
activation independently of Rheb, Rag GTPases, TSC2, PKB, MAPK and AMPK, indicating that cAMP may act
independently of known regulatory inputs into mTOR. Moreover, we show that the prolonged elevation in
[cAMP]i can also inhibit mTORC2. We provide evidence that this cAMP-dependent inhibition of mTORC1/2 is
caused by the dissociation of mTORC1 and 2 and a reduction in mTOR catalytic activity, as determined by its
auto-phosphorylation on Ser2481. Taken together, these results provide an important insight into how cAMP
signals to mTOR and down-regulates its activity, which may lead to the identiﬁcation of novel drug targets to
inhibit mTOR that could be used for the treatment and prevention of human diseases such as cancer.hysiology and Pharmacology,
Wellcome Building, University
.: +44 116 229 7148; fax:+44
 license. © 2011 Elsevier Inc. Open access under CC BY license. 1. Introduction
Mammalian target of rapamycin (mTOR, also known as FRAP, RAFT
or RAPT) is a Ser/Thr protein kinase that exists in two biochemically
and functionally distinct multi-component complexes known as
mTORC1 and mTORC2 [1,2]. mTORC1 couples nutrient availability
with hormonal and growth factor signals to regulate metabolism, cell
growth and proliferation [3,4], and phosphorylates a number of
proteins involved in protein translation including ribosomal protein S6
kinases 1 and 2 (S6K1/2) and eukaryotic initiation factor 4E binding
proteins (4EBPs) [5]. mTORC1 activity is regulated by numerous sig-
nalling pathways, many of which converge on tuberous sclerosis
complex 1 and 2 (TSC1/2) [3]. TSC1/2 serves as a GTPases activating
protein (GAP) for the small G-protein Rheb which in its GTP-bound
state binds to and activates mTORC1. The association of Rheb and
mTOR is promoted by amino acids availability [6]. It was reported that
amino acids recruit mTORC1 to Rab7 positive vesicular structurescontaining Rheb via Rag GTPases and the trimeric “ragulator” [7,8].
mTORC2 is also important in the regulation of cell growth and
proliferation and has been implicated in the organization of actin
cytoskeleton [1]. These effects are mediated by mTORC2 dependent
phosphorylation of AGC (for protein kinase A, G and C) kinase family
members, such as protein kinase B (PKB), protein kinase C (PKC) and
serum/glucocorticoid-induced kinase 1 (SGK1), which leads to their
stabilization and full activation.
The second messenger cAMP (cyclic adenosine monophosphate)
is yielded in response to a broad range of extracellular stimuli that act
upon G-protein coupled receptors (GPCR) [9]. cAMP is synthesized
by the action of adenylate cyclase (AC) and its degradation is
mediated by the action of cAMP phosphodiesterases (PDEs) [10,11].
Most of the effects of cAMP are dependent upon the activation of
its downstream effectors protein kinase A (PKA) [12] and exchange
protein directly activated by cAMP (EPAC) [13]. Like mTOR, a diverse
array of biological processes is regulated by cAMP [14]. Interestingly,
there is good evidence of crosstalk between these two pathways.
For instance, cAMP can either stimulate [15–20] or inhibit [21–26]
mTORC1 depending upon cell type. This is likely through the acti-
vation or suppression of signalling transduction cascades upstream
of mTORC1 such as the PKB [16,26–29], the MAPK (mitogen-
activated protein kinase) [30] and the AMPK (AMP-activated protein
1928 J. Xie et al. / Cellular Signalling 23 (2011) 1927–1935kinase) pathways [23,25,31,32]. For example, glucagon, a GsPCR
agonist that increase [cAMP]i, inhibits mTORC1 in rat hepatocytes
[23,25]. This is coincident with an increase in AMPK phosphorylation
on Thr172 [23,25], a positive regulator of TSC1/2 [33]. Of particular
interest is that cAMP has anti-proliferative effects on cancer cells,
which can be mediated by either targeting cell cycle regulatory
molecules [24,34,35], or cellular signalling pathways pivotal to cell
cycle progression [30]. It is possible that the anti-proliferative effects
of cAMP are mediated, at least in part, by the inhibition of mTORC1
[24], as the over-activation of mTORC1 has been implicated in the
development and maintenance of tumours [4].
In this report we demonstrate, in mouse embryonic ﬁbroblasts
(MEFs) and human embryonic kidney cells (HEK293), that cAMP
signals to and inhibits mTORC1/2 via their dissociation and a decrease
in mTOR intrinsic catalytic activity. We provide evidence that this is
mediated by a novel PKA-dependent mechanism which is indepen-
dent of TSC2, Rheb and Rag GTPases. This report provides new insights
into how cAMP talks to mTOR and could lead to the discovery of new
anti-cancer drug targets.
2. Materials and methods
2.1. Chemicals
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO),
unless speciﬁed.
2.2. Cell culture and treatments
TSC2+/+/p53−/− MEFs (mouse embryonic ﬁbroblasts), TSC2−/−/
p53−/− MEFs (kindly provided by Dr. David J. Kwiatkowski (Harvard
Medical School, Boston, MA)) [36] and HEK293 (human embryonic
kidney) cells were grown to approximately 80% conﬂuence prior to
treatment. MEFs were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) containing 25 mM glucose, supplemented with 10% (v/v)
heat-inactivated foetal bovine serum (FBS) (Invitrogen, Carlsbad, CA),
100 μg/ml streptomycin, 100 units/ml penicillin sulphate, 100 units/ml
neomycin, 50 μMβ-mercaptoethanol and1×non-essential aminoacids.
HEK293 cells were grown in DMEM containing 25 mM glucose,
supplemented with 10% (v/v) heat-inactivated FBS, 100 μg/ml strepto-
mycin, 100 units/ml penicillin sulphate and 100 units/ml neomycin.
Cells were incubated at 37 °C in 5% CO2 and 95% air.
Prior to treatments (unless speciﬁed in the ﬁgure legends) the
media were removed and the cells were washed twice and incubated
with modiﬁed Krebs–Ringer bicarbonate buffer (KRB) (115 mM NaCl,
5 mM KCl, 10 mM NaHCO3, 2.5 mM MgCl2, 2.5 mM CaCl2, 20 mM
HEPES, pH 7.4), supplemented with 0.5× MEM amino acids solution
(50× stock), 0.5× MEM non-essential amino acids solution (100×
stock) and 0.5×L-glutamine (100× stock).
After treatment (unless speciﬁed in the ﬁgure legends), cells were
lysed by the addition of ice cold lysis buffer (1% (v/v) Triton, 10 mM
β-glycerophosphate, 50 mM Tris–HCl, pH 7.5, 1 mM EDTA, 1 mM
EGTA, 1 mM sodium orthovanadate, 1 mM benzamidine–HCl, 0.2 mM
phenylmethylsulfonyl ﬂuoride, 1 μg/ml each of leupeptin and pep-
statin, 0.1% (v/v) β-mercaptoethanol and 50 mM NaF). Lysates were
then centrifuged for 10 min at 16,000g. The supernatants were kept,
and total protein concentrations were determined by Bradford assay
(Bio-Rad, Hercules, CA). Normalized lysates were stored at −20 °C
until further analysis.
2.3. Adenoviral infection
Recombinant adenovirus expressing dominant negative AMPK
was kindly provided by Dr. Ian Salt (University of Glasgow, UK) [37].
The cells were infected as previously described [38].2.4. Transfection
HA tagged S6K1 (HA-S6K1) pRK7 vector was kindly provided by
Prof. John Blenis (Harvard Medical School, Boston, MA, USA) [39], FLAG
tagged Rheb (FLAG-Rheb) (plasmid 19996, Addgene, Cambridge, MA)
and myc tagged mTOR (myc-mTOR) (plasmid 1861, Addgene, Cam-
bridge, MA) were subcloned into the pRK7 vector. RagBGTPQ99L and
RagCGDPS75L were described previously [40]. Cells were transfected by
the CaCl2 method as previously described [41]. Cells were incubated for
24 h in DMEM prior to serum starvation for 18 h. Details of treatments
are described in the ﬁgure legends.
2.5. Immunoprecipitation
The immunoprecipitation of mTORC1 and 2 complexes was
essentially performed as previously described [40]. Brieﬂy, after
treatment, cells were lysed in 0.3% (w/v) CHAPS buffer (1 M HEPES
pH7.5, 120 mM NaCl, 1 mM EDTA pH8, 10 mM sodium pyrophos-
phate, 10 mM β-glycerolphosphate, 50 mM NaF, 0.5 mM sodium
orthovanadate, 0.3% CHAPS, 1 mM benzamidine-HCl, 0.2 mM phenyl-
methylsulfonyl ﬂuoride, 1 μg/ml each of leupeptin and pepstatin).
Protein lysates were then centrifuged for 10 min at 16,000g. The super-
natants were kept, and total protein concentrations were determined
by the Bradford assay. Lysates containing 1.2 mg of protein were
incubatedwith anti-myc antibody (Sigma) for 16 h at 4 °Cwith rotation,
followed by the incubationwith protein-G sepharose beads for a further
period of 2 h at 4 °C with rotation. Beads were washed three times
with 0.3% (w/v) CHAPS buffer, and then resuspended in 2× Laemmli
sample buffer.
2.6. SDS-PAGE and Western blotting
SDS-PAGE and Western blotting were performed as described
previously [17]. Anti-PKCα was obtained from BD Transduction
Laboratories (Oxford, UK). Anti-rpS6, GAPDH and Rheb were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antiphospho-rpS6
Ser235/Ser236, rpS6 Ser240/Ser244, S6K1 Thr389, 4EBP1 Ser65, PKB
Ser473, PRAS40 Thr246, ERK Thr202/Tyr204, AMPK Thr172, PKCα/βII
Thr638/Thr641, mTOR Ser2481, mTOR Ser2448, as well as anti-S6K1,
4EBP1, PKB, AMPK, mTOR, RAPTOR, RICTOR, mLST8 and PRAS40 were
purchased from Cell Signalling Technologies (Beverly, MA, USA).
2.7. Measurement of cAMP
Cells were grown in 24-well tissue culture plates. After treatment,
buffer was removed and ice cold 0.5 M trichloroacetic acid was added.
cAMPwas extracted and determined using a radioreceptor assay with
binding protein puriﬁed from calf adrenal glands as previously
described [42]. [cAMP]i was measured by interpolation of a standard
curve and related to cellular protein, which was assessed by Bradford
assay.
3. Results
3.1. cAMP inhibits insulin stimulated mTORC1 activation in HEK293 cells
and MEFs
Todetermine the effect of cAMPonmTORC1 activation,HEK293 cells
were pretreated with forskolin, a deterpene that activates adenylyl
cyclase [43], and IBMX (3-isobutyl-1-methylxanthine) that suppresses
PDEs [10]) to elevate [cAMP]i, (Fig. 1B) prior to the addition of insulin. As
anticipated, forskolin and IBMX treatment caused the PKA-dependent
phosphorylation of rpS6 (ribosomal protein S6) on Ser235/Ser236 [17],
yet had no effect on the phosphorylation of Ser240/Ser244, a
downstream target of S6K activation that is routinely used as a
readout of mTORC1 activity [5] (Fig. 1A). Insulin alone led to a decrease
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ylation and activation, and the rapid (within 5 to 10 min) phosphor-
ylation of rpS6 on Ser240/Ser244. However, in cells pretreated with
forskolin and IBMX (Fig. 1A), insulin-stimulated mTORC1 activation
was suppressed as determined by the phosphorylation of rpS6 on
Ser240/Ser244. These results demonstrate that, under these con-
ditions, cAMP inhibits insulin-stimulated mTORC1 activation in
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activation was also ascertained in mouse embryonic ﬁbroblasts
(MEFs). In these cells, insulin also stimulated mTORC1 as determined
by the phosphorylation of its downstream targets S6K1 on Thr389 and
4EBP1 on Ser65 and the phosphorylation of rpS6 on Ser240/Ser244
and a decrease in the electrophoretic mobility of S6K1 (Fig. 1C). In
addition, insulin treatment led to an increase in the phosphorylation
of PKB on Ser473, an indicator of its activation state [44]. PKB can
activate mTORC1 through the phosphorylation and inactivation of
TSC2, an upstream inhibitor of mTORC1 [45], and the phosphoryla-
tion of PRAS40 on Thr246 [46–48]. Indeed, insulin stimulated the
phosphorylation of PRAS40 on Thr246 (Fig. 1C). The preincubation of
cells with increasing concentrations of forskolin in the presence of
IBMX, which was to dose dependently increase [cAMP]i (Fig. 1D),
suppressed insulin-stimulated mTORC1 activation as determined by
the phosphorylation of S6K1 on Thr389, 4EBP1 on Ser65, rpS6 on
Ser240/Ser244 and the electrophoretic mobility of S6K1. This paralleled
a decrease in the phosphorylation of PKB at Ser473 and PRAS40 on
Thr246 (Fig. 1C). Therefore, in MEFs, cAMP-dependent inhibition of
mTORC1may bemediated via the inhibition of PKB. TheMAPK pathway
is unlikely to be involved as insulin treatment of MEFs had no effect on
the phosphorylation of ERK (extracellular signal-regulated kinase)
(Fig. 1C).
3.2. cAMP inhibits mTORC1 independently of TSC2
In order to explore the molecular mechanism by which cAMP
inhibitsmTORC1, we investigatedwhether cAMP could inhibitmTORC1
in cells deleted of TSC2. TSC2 knock-out (TSC2−/−) MEFs were pre-
treated with increasing concentrations of forskolin plus IBMX in the
absence or presence of insulin (Fig. 2). mTORC1 is constitutively
activated in these cells due to inactivation of the TSC1/2 complex [49].
Therefore, S6K1 and 4EBPs are constitutively hyper-phosphorylated in
serum starved cells and insulin treatment is unable to further stimulate
mTORC1. Importantly, incubation of these cells with forskolin/IBMX
dose-dependently suppressed the phosphorylation of S6K1 (Thr389)
and 4EBP1 (Ser65) (Fig. 2). This demonstrates that cAMP can inhibit
mTORC1 independently of TSC1/2 and potentially reveals a novel and
additional mechanism by which cAMP inhibits mTORC1. Moreover, no
change in the phosphorylation state of PRAS40 was detected indicating
that the suppressionofmTORC1 activity is likely independent of PRAS40
in these cells (Fig. 2).
3.3. AMPK is not involved in the inhibition of mTORC1 by cAMP
Glucagon, a GsPCR agonist which augments [cAMP]i, can inhibit
mTORC1 and this has been shown to correlate with the phosphory-
lation of AMPK [23,25]. Interestingly, AMPK can also block the activity
of mTORC1 independently of TSC1/2 via the phosphorylation of
RAPTOR [50]. To investigate whether the inhibitory effect of cAMP
could bemediated by AMPK; TSC2+/+ (Fig. 3A) and TSC2−/− (Fig. 3B)
MEFs were infected with adenovirus expressing dominant-negativeFig. 1. cAMP inhibits insulin signalling to mTOR. A) and B) HEK293 cells or C) and
D) TSC2+/+MEFs were serum starved in DMEM for 16 h before preincubated in KRB for
30 min, then incubated in KRBwith or without forskolin (Fsk) (10 μM in A/B) plus IBMX
(1 mM) for 30 min, before treatment with insulin (100 nM) or TPA (1 μM) for a further
30 min as indicated. A) and C) Proteins were resolved by SDS-PAGE and Western
blotted using antisera against phosphorylated (P)- rpS6 Ser240/Ser244 (S240/244),
Ser235/Ser236 (S235/236), P-S6K1 Thr389 (T389), P-4EBP1 Ser65 (S65), P-PKB Ser473
(S473), P-PRAS40 Thr246 (T246), P-Erk1/2, as well as S6K1, rpS6 and 4EBP1. S.E.: short
exposure; L.E.: long exposure. [cAMP]i levels in B) and D) were determined and
expressed relative to cellular protein content, and shown as means±SE; n=3. In
B), ***Pb0.001 versus time-matched control (no Fsk and IBMX) as indicated. There was
no signiﬁcant effect of insulin treatment on cAMP levels. For clarity, not all differences
are shown. In C), ***Pb0.001 as indicated. Statistical analyses were by Bonferroni's test
following one-way ANOVA. Immunoblots are representative of three independent
experiments.
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Fig. 2. cAMP inhibits theactivationofmTORC1 independently of TSC2. TSC2−/−or TSC2+/+
MEFs were serum starved in DMEM for 16 h before preincubation in KRB for 30 min,
followedby incubation inKRBwith orwithout forskolin (0.1–10 μM)plus IBMX(1 mM) for
30 min. Cellswere then treatedwith insulin (100 nM) or TPA (1 μM) for a further 30 minas
indicated. Cell lysateswere separated by SDS-PAGE and subjected to immunoblotting with
antisera against phosphorylated (P)- rpS6 Ser240/Ser244 (S240/244), P-S6K1 Thr389
(T389), P-4EBP1 Ser65 (S65), P-PKB Ser473 (S473), P-PRAS40 Thr246 (T246), P-Erk1/2, as
well as S6K1, rpS6 and 4EBP1. Levels of P-S6K1 Thr389 and P-4EBP1 Ser65were quantiﬁed
by densitometric analysis and are presented as arbitrary units (A.U.). Results shown are
means±SE; n=3. *Pb0.05, **Pb0.01, ***Pb0.001 by Dunnett's test following one-way
ANOVA. Immunoblots are representative of three independent experiments.
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Fig. 3. AMPK is not involved in the inhibition of mTORC1 by cAMP. A) TSC2+/+ and
B) TSC2−/−MEFs were infected with the recombinant adenovirus expressing dominant
negative (DN) AMPK for 32 h. Cells were serum starved in DMEM for 16 h before
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(T389), P-AMPK Thr172 (T172), P-4EBP1 Ser65 (S65), as well as AMPK, rpS6 and 4EBP1.
All results are representative of three independent experiments.
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AICAR (5-Aminoimidazole-4-carboxamide ribotide) induced phos-
phorylation of AMPK, yet cAMP was still able to suppress insulin-
mediated mTORC1 activation in both TSC2+/+ and TSC2−/− cells, as
determined by the phosphorylation status of S6K1 and 4EBP1 (Fig. 3A
and B). In addition, we were unable to detect any increase in AMPK
phosphorylation in cells treated with forskolin and IBMX. Therefore,
we conclude that an elevation in [cAMP]i can inhibit mTORC1 inde-
pendently of AMPK activity.
3.4. cAMP inhibits amino acid signalling to mTORC1
Amino acids alone are able to stimulate mTORC1 via a mechanism
that bypasses TSC1/2 and Rheb [51]. To investigate whether cAMP can
suppress mTORC1 activity driven by amino acids, TSC2+/+ and
TSC2−/−MEFs were incubated in the absence or presence of forskolinand IBMX prior to activation of mTORC1 by the addition of amino
acids (Fig. 4A). As anticipated, the activity of mTORC1was augmented
in response to amino acids in both TSC2+/+ and TSC2−/− cells as
demonstrated by the phosphorylation of S6K1 (Thr389) and 4EBP1
(Ser65) and a decrease in the electrophoretic mobility of S6K1 and
4EBP1 (Fig. 4A). PKB, PRAS40 and ERK were not phosphorylated upon
amino acids treatment. Interestingly, amino acid stimulated mTORC1
activation was attenuated in cells treated with forskolin/IBMX
indicating that cAMP inhibits mTORC1 independently of TSC1/2 and
Rheb (Fig. 4A).
The over-expression of Rheb can overcome the effect of amino
acids depletion and constitutively activate mTORC1 [51,52]. There-
fore, to provide additional evidence that the effect of cAMP on
mTORC1 is independent on Rheb, TSC2−/− MEFs (Fig. 4B) and
HEK293 cells (Fig. 4C) were co-transfected with FLAG tagged Rheb
(FLAG-Rheb) and HA tagged S6K1 (HA-S6K1). As anticipated, Rheb
over-expression caused the constitutive activation of mTORC1, even
in the absence of amino acids, as determined by the phosphoryla-
tion of S6K1 on Thr389 (Fig. 4B and C). Importantly, in Rheb over-
expressing cells, the phosphorylation of S6K1 was attenuated in the
presence of forskolin/IBMX in both TSC2−/− MEFs and HEK293s
(Fig. 4B and C). These results provide evidence that the inhibitory
effect of cAMP on mTORC1 is independent of Rheb.
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1931J. Xie et al. / Cellular Signalling 23 (2011) 1927–1935Rag GTPases are crucial for amino acids signalling to mTORC1 [7,53].
In order to study whether cAMP is exerting its inhibitory effect through
Rag GTPases, active Rag GTPases (RagBGTPQ99L and RagCGDPS75L, as
reported previously in ref. [7]) and HA-S6K1 were co-transfected in
HEK293 cells, cells were incubated in KRB in the absence of amino
acids. As amino acids play a permissive role in insulin signalling to
mTORC1 [54], insulin alone was unable to induce the phosphorylation
of S6K1 (Fig. 4D). In contrast, the over-expression of active Rag GTPases
evoked the phosphorylation of S6K1, which was potentiated by the
addition of insulin. Treatment of cells with forskolin/IBMXwas still ableto inhibit mTORC1 in the presence of active Rag GTPases (Fig. 4D).
These results indicate that inhibition of mTORC1 by cAMP is
independent of the role of active Rag GTPases in mTORC1 activation.
3.5. cAMP inhibits mTORC1 via PKA
PKA is a major effector of cAMP [55]. To determine whether the
inhibitory effect of cAMP on mTORC1 is mediated through PKA,
HEK293 cells were pretreated with the PKA selective inhibitor H89
prior to forskolin and IBMX treatment. As anticipated, amino acids
1932 J. Xie et al. / Cellular Signalling 23 (2011) 1927–1935stimulated the phosphorylation of S6K1 on Thr389 and this was in-
hibited by increased [cAMP]i (Fig. 5). As expected, H89 dose-
dependently inhibited the phosphorylation of rpS6 in Ser236/236
which is mediated by PKA [17]. Importantly this correlated with the
recovery of S6K1 phosphorylation on Thr389 (Fig. 5), indicating that
the inhibitory effect of cAMP on mTORC1 is likely mediated by PKA.
3.6. Increased [cAMP]i causes dissociation of mTOR complexes and the
inhibition of mTOR catalytic activity
The results so far indicate that cAMP inhibits mTORC1 via the
activation of PKA and that PKA inhibits mTORC1 independently of
the classical regulatory inputs upstream of mTORC1. One possibility is
that an elevation in [cAMP]i causes the PKA-dependent dissociation of
mTORC1. Therefore, we investigated whether the integrity of mTOR
complexes is disturbed upon increases in [cAMP]i. For this purpose,
HEK293 cells transfected with myc-tagged mTOR (myc-mTOR) were
incubated with forskolin and IBMX prior to stimulation with serum,
myc-mTOR and associated proteins were then immunoprecipitated
from these cells. In serum repleted cells mTORC1 was active as deter-
mined by the phosphorylation status of S6K1. In addition, mLST8 and
the mTORC1 speciﬁc components RAPTOR and PRAS40, and the
mTORC2 speciﬁc component RICTOR were co-immunoprecipitated
with myc-mTOR, indicating the integrity of mTORC1 and mTORC2
under these conditions. As expected, the preincubation of cells with
forskolin/IBMX inhibited serum-stimulated mTORC1 activity, as
determined by the phosphorylation status of S6K1. Moreover, pre-
incubation of cells with forskolin/IBMX caused the dissociation of
the mTORC1 speciﬁc component RAPTOR and PRAS40. In addition,
forskolin/IBMX caused the dissociation of the mTORC2 speciﬁc com-
ponent RICTOR from myc-mTOR. The association of mLST8 to myc-
mTOR was unaffected (Fig. 6A). In conclusion, elevations in [cAMP]i
lead to the dissociation of mTORC1 and mTORC2.
To further investigate the molecular mechanism by which cAMP
inhibits mTORC1, we monitored the auto-phosphorylation of mTOR
on Ser2481, which has been shown to be a biomarker for intrinsicAmino acids (5X)
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Fig. 5. The inhibition ofmTORC1 is PKA dependent. A) TSC2−/−MEFs and B)HEK293 cells
were serum-starved in DMEM for 16 h. For A), cells were incubated in KRB supplemented
with 0.5× amino acids. For B), cells were incubated in KRB supplemented with 20 mM
glucose but in the absence of amino acids. For both A) and B), after 30 min, cells were
treated with increasing concentrations of H89, a PKA inhibitor, for 30 min, followed by
treatment with forskolin (10 μM) and IBMX (1 mM) for 30 min, before stimulation with
amino acids (5×) for a further period of 30 min (for B)). Proteins were resolved on
SDS-PAGE andWestern blotted using antibodies against phosphorylated (P)-S6K1 Thr389
(T389), P-rpS6 Ser235/236 (S235/236), and as a loading control, rpS6. All results are
representative of three independent experiments.mTORC-speciﬁc catalytic activity [56]. In TSC2−/− MEFs and insulin-
stimulated or FLAG-Rheb transfected HEK293 cells, forskolin/IBMX
treatment led to a reduction in the phosphorylation of mTOR on
Ser2481 (Fig. 6B). Interestingly, the phosphorylation of mTOR on
Ser2448, which has been reported to be mediated by S6K1 [57,58],
was unaffected by cAMP, whereas rapamycin treatment led to a re-
duction in the phosphorylation of mTOR on both sites (Ser2481 and
Ser2448) (Fig. 6B).
Taken together, these results suggest that cAMP inhibits mTORC1
via the perturbation of mTOR complex assembly and the reduction of
mTOR catalytic activity.
3.7. cAMP inhibits mTORC2
As Forskolin/IBMX leads to the dissociation of mTORC2 and a
decrease in mTOR activity it seems likely that elevations [cAMP]i may
also inhibit mTORC2. mTORC2 phosphorylates the turn motif on PKB,
PKCα and PKCβII, resulting in their destabilisation anddegradation [1].
mTORC2 is also responsible for the phosphorylation of PKB on Ser473
[59]. Therefore, to determine whether mTORC2 is also inhibited by
[cAMP]i, TSC2+/+MEFswere treatedwith forskolin and IBMX for up to
24 h and the phosphorylation and expression of PKB, PKCα and PKCβII
were determined. Incubation of cells with Forskolin/IBMX caused a
time-dependent reduction in turn motif phosphorylation on PKB,
PKCα and PKCβII, and this paralleled a decrease in the protein levels of
PKB and PKCα (Fig. 7A). These results provide evidence that elevation
of [cAMP]i not only inhibits mTORC1 (Figs. 1–4) but also inhibits
mTORC2 (Fig. 7).
4. Discussion
cAMP and mTOR signalling pathways regulate fundamental
cellular processes including metabolism, protein synthesis, prolifer-
ation and cell survival [60,61]. Therefore, it is of immense interest to
understand the signalling events which integrate these two signalling
pathways. In this study,we provide evidence that cAMP is able to inhibit
the activation of mTORC1 and mTORC2 and this is likely mediated
through the PKA-dependent disruption of themTOR complexes 1 and 2
and the inhibition of mTOR catalytic activity.
Hormones and growth factors can activate mTORC1 via the PKB-
and/or ERK/RSK-dependent phosphorylation of TSC2 and the inacti-
vation of the TSC1/2 complex [3]. However, in some cell types, cAMP
inhibits these signalling pathways [16,23,25–32] and hence inhibits
hormone and growth factors activation of mTORC1. However, we
demonstrate that cAMP can inhibit mTORC1 independently of these
signalling pathways and independently of TSC1/2. Therefore, this
work reveals an alternative and/or additional mechanism by which
cAMP can inhibit mTORC1 in mammalian cells.
mTORC1 can also be regulated by the intracellular localization of
Rheb independently of TSC1/2 [7,8]. For example, amino acids promote
the co-localisation of mTOR with Rheb through a Rag GTPase depen-
dentmechanism,whichalone canactivatemTORC1 [7,53]. Interestingly,
the over-expression of Rheb can overcome the inhibitory effect of
amino acids withdrawal and this is thought to be mediated by the
inappropriate co-localisation of Rheb with mTORC1 [7,8]. It is unlikely
that the inhibitory effect of cAMP onmTORC1 is caused by an alteration
of the intracellular localization of Rheb as we show that forskolin/IBMX
is able to reducemTORC1activityunder conditionswhereRhebor active
Rag GTPases are over-expressed (Fig. 4). However, we cannot exclude
the possibility that cAMP perturbs Rheb-GTP loading independently of
TSC1/2, perhaps through impinging on its guanine nucleotide exchange
factor.
Although themolecular mechanism by which cAMP inhibits mTOR
is not fully understood, it is dependent on the activation of PKA
(Fig. 5). One possibility is that PKA directly phosphorylates mTOR and
inhibits mTOR kinase activity. Indeed, cAMP inhibits mTOR intrinsic
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Fig. 6. cAMP leads to dissociation of the mTOR complexes and inhibits the catalytic activity of mTOR. A) HEK293 cells were transfected with myc-tagged mTOR (myc-mTOR). At 32 h
post-transfection, cells were serum-starved in DMEM for 16 h before preincubation in Dulbecco's-PBS for 30 min, and then stimulation with DMEM supplemented with 10% serum in
the presence or absence of forskolin (10 μM) and IBMX (1 mM) for 1 h. Cell lysates were immunoprecipitated with anti-myc antibodies and immunoblotted as indicated. Levels of
RAPTOR, RICTOR, mTOR, mLST8 and PRAS40 from immunoprecipitation were quantiﬁed by densitometric analysis. Results are means±SE. *Pb0.05 by Student's paired t-test, n=3
where the analysis was performed on the raw absorbance data. B) TSC2−/−MEFs and HEK293 cells were serum-starved in DMEM for 16 h before preincubation in KRB for 30 min,
then incubation in KRB with forskolin (10 μM) plus IBMX (1 mM) for 30 min, before further treatment with insulin (100 nM) for another period of 30 min. HEK293 cells were also
co-transfected with FLAG-Rheb and HA-S6K 48 h prior to the experiment. Cell lysates were separated on SDS-PAGE and subjected to immunoblotting with antisera against
phosphorylated (P)- mTOR Ser2481 (S2481), Ser2448 (S2448), S6K1 Thr389 (T389), and as loading controls, mTOR and exogenous Rheb (FLAG-Rheb). All results are representative
of three independent experiments.
1933J. Xie et al. / Cellular Signalling 23 (2011) 1927–1935catalytic activity as determined by the auto-phosphorylation state of
mTOR on Ser2481 (Fig. 6B) and, interestingly, PKA has been reported
to be associated with mTOR [62]. However, we and others have been
unable to signiﬁcantly phosphorylate mTOR in vitrowith recombinantcatalytic subunit of PKA (PKAc) (Xie, J. and Herbert, T.P., unpublished
data, and [21]). On the other hand, it has been reported that glucagon,
which elevates [cAMP]i, stimulates an increase in the phosphorylation
of mTORC1 on Ser2448 in hepatocytes and this correlates with
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Fig. 7. cAMP inhibits mTORC2. A) TSC2+/+ MEFs were maintained in growth media,
treated with forskolin (10 μM) and IBMX (1 mM) for 6, 16 or 24 h. Cell lysates were
resolved by SDS-PAGE, followed by Western blotting of phosphorylated (P)- PKCα/βII
turn motif (TM), P-PKB TM, P-PKB Ser473 (S473), total PKCα and total PKB. GAPDHwas
used as a loading control. P-PKCα/βII TM, PKCα, P-PKB TM and PKB levels were
quantiﬁed by densitometric analysis. B) [cAMP]i levels were determined and expressed
relative to cellular protein content. Results are means±SE. *Pb0.05 **Pb0.01
***Pb0.001 versus control (untreated) using one-way ANOVA followed by Dunnett's
test, n=3where the analysis was performed on the raw absorbance data. Immunoblots
are representative of three independent experiments.
1934 J. Xie et al. / Cellular Signalling 23 (2011) 1927–1935decreased mTORC1 activity [22]. However, this is unlikely to be the
mechanism of inhibition as the mutation of this site has no effect on
mTORC1 kinase activity [22,63]. Moreover, we could not detect any
changes in the phosphorylation of mTOR on Ser2448 in response to
elevated [cAMP]i in either HEK293 cells or MEFs (Fig. 6B).Importantly, we show that increased [cAMP]i leads to the
dissociation of both mTORC1 and 2 (Fig. 7A), which is known to
inhibit both mTORC1 and mTORC2 activity [64–66]. For example,
upon rapamycin treatment, mTORC1 dimerization is compromised
and the complex is disassembled in a time-dependent manner [67].
However, whether complex dissociation as a result of increased
[cAMP]i follows the inactivation of mTOR or that mTOR inactivation
follows the dissociation of the complex is unclear.
The phosphorylation of PRAS40 at Thr246 by PKB has been reported
to promotemTORC1 activation through the dissociation of PRAS40 from
mTOR [46–48]. To our surprise, the binding of PRAS40 to mTOR was
reduced even though PRAS40 phosphorylation on Thr246 was ablated
in response to cAMP (Fig. 7A). This raises doubt as to whether Thr246
can be used as an indicator of PRAS40 binding to mTORC1. As PRAS40
binds to RAPTOR within the complex [46,67,68], the dissociation of
PRAS40 from mTOR upon forskolin/IBMX treatment is likely caused by
the dissociation of RAPTOR.
During cancer development, themTOR pathway is often abnormally
up-regulated, which favours cancer cell survival, growth, replication,
angiogenesis and metastasis [4]. Therefore, the inhibition of mTOR is a
potential treatment for certain forms of cancer [69–71]. Similarly, cAMP
negatively regulates cell cycle progression and cell motility in cancer
cells, and therefore the augmentation of [cAMP]i is a promising future
cancer treatment [24,64,72–74]. It can be tempting to speculate that at
least part of theanti-proliferativeeffect of cAMP ismediated through the
inhibition of mTOR. However, cAMP can also target a number of cell
cycle regulators such as p21Cip1, p27Kip1, Rb (retinoblastoma protein)
[34,35] and CDK4 (cyclin D dependent kinase 4) [24]. Therefore, it is
difﬁcult to differentiate mTOR dependent and independent effects of
cAMP on the control of proliferation.
In conclusion, we show that elevation of [cAMP]i suppresses
mTORC1/2 by promoting mTOR complex disassembly and inhibiting
mTOR's intrinsic catalytic activity. These observations provide new
insights into the crosstalk between cAMP and mTOR, which may also
contribute to the design of novel mTOR inhibitors for future strategies
in the ﬁght against cancer.
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